Faculty Opinions recommendation of Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Author(s):  
Mellar Davis
BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e040061
Author(s):  
Getinet Ayano ◽  
Asmare Belete ◽  
Bereket Duko ◽  
Light Tsegay ◽  
Berihun Assefa Dachew

ObjectivesTo assess the global prevalence estimates of depressive symptoms, dysthymia and major depressive disorders (MDDs) among homeless people.DesignSystematic review and meta-analysis.Data sourcesDatabases including PubMed, Scopus and Web of Science were systematically searched up to February 2020 to identify relevant studies that have reported data on the prevalence of depressive symptoms, dysthymia and MDDs among homeless people.Eligibility criteriaOriginal epidemiological studies written in English that addressed the prevalence of depressive problems among homeless people.Data extraction and synthesisA random-effect meta-analysis was performed to pool the prevalence estimated from individual studies. Subgroup and sensitivity analyses were employed to compare the prevalence across the groups as well as to identify the source of heterogeneities. The Joanna Briggs Institute’s quality assessment checklist was used to measure the study quality. Cochran’s Q and the I2 test were used to assess heterogeneity between the studies.ResultsForty publications, including 17 215 participants, were included in the final analysis. This meta-analysis demonstrated considerably higher prevalence rates of depressive symptoms 46.72% (95% CI 37.77% to 55.90%), dysthymia 8.25% (95% CI 4.79% to 11.86%), as well as MDDs 26.24% (95% CI 21.02% to 32.22%) among homeless people. Our subgroup analysis showed that the prevalence of depressive symptoms was high among younger homeless people (<25 years of age), whereas the prevalence of MDD was high among older homeless people (>50 years of age) when compared with adults (25–50 years).ConclusionThis review showed that nearly half, one-fourth and one-tenth of homeless people are suffering from depressive symptoms, dysthymia and MDDs, respectively, which are notably higher than the reported prevalence rates in the general population. The findings suggest the need for appropriate mental health prevention and treatment strategies for this population group.


2019 ◽  
Vol 101 ◽  
pp. 138-149 ◽  
Author(s):  
Sinha Engel ◽  
Sebastian Laufer ◽  
Christine Knaevelsrud ◽  
Sarah Schumacher

2020 ◽  
Vol 45 (2) ◽  
pp. 133-144 ◽  
Author(s):  
Amelia J Scott ◽  
Louise Sharpe ◽  
Max Loomes ◽  
Milena Gandy

Abstract Objective The aim of this systematic review and meta-analysis was to provide an estimate of the prevalence of anxiety and depressive disorders in youth with epilepsy (YWE). It also aimed to calculate the overall magnitude of observed differences in anxiety and depressive symptoms reported by YWE compared with healthy controls and investigate whether any factors moderated anxiety and depression outcomes in YWE. Methods Following prospective registration, electronic databases were searched up until October 2018. Studies were included if they reported on the rate of anxiety or depression in samples of YWE, and/or if they used valid measures of anxious or depressive symptomatology in YWE compared with a healthy control sample. Results Twenty-three studies met inclusion criteria. The overall pooled prevalence of anxiety disorders in YWE was 18.9% (95% confidence interval [CI] 12.0%–28.5%), and for depression the pooled prevalence was 13.5% (95% CI 8.8%–20.2%). In samples of YWE compared with healthy controls, significantly higher anxiety (d = 0.57, 95% CI 0.32–0.83, p &lt; .000) and depressive (d = 0.42, 95% CI 0.16–0.68, p &lt; .000) symptomatology was reported. Conclusions YWE report anxiety and depressive disorders and symptoms to a significantly higher degree than youth without epilepsy. There is also evidence that certain anxiety disorders (e.g. generalized anxiety disorder, separation anxiety disorder) are particularly elevated, perhaps reflecting the unique impact of epilepsy on youth psychopathology. Research is needed to understand the risk factors associated with anxiety and depressive disorders in epilepsy, and better understand how these symptoms change across development.


2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Amanda J. Baxter ◽  
Andrew Page ◽  
Harvey A. Whiteford

Background. Depressive disorders are associated with substantial risk of premature mortality. A number of factors may contribute to reported risk estimates, making it difficult to determine actual risk of excess mortality in community cases of depression. The aim of this study is to conduct a systematic review and meta-analysis of excess mortality in population-based studies of clinically defined depression. Methods. Population-based studies reporting all-cause mortality associated with a clinically defined depressive disorder were included in the systematic review. Estimates of relative risk for excess mortality in population-representative cases of clinical depressive disorders were extracted. A meta-analysis was conducted using Stata to pool estimates of excess mortality and identify sources of heterogeneity within the data. Results. Twenty-one studies reporting risk of excess mortality in clinical depression were identified. A significantly higher risk of mortality was found for major depression (RR 1.92 95% CI 1.65–2.23), but no significant difference was found for dysthymia (RR 1.37 95% CI 0.93–2.00). Relative risk of excess mortality was not significantly different following the adjustment of reported risk estimates. Conclusion. A mortality gradient was identified with increasing severity of clinical depression. Recognition of depressive symptoms in general practice and appropriate referral for evidence-based treatment may help improve outcomes, particularly in patients with comorbid physical disorders.


2021 ◽  
Author(s):  
Karla Natally Santos ◽  
Mayk Rodolfo de Jesus Santana ◽  
Giselle de Carvalho Brito ◽  
Luciana Pereira Lobato

Abstract Background: Depression is a chronic condition of high prevalence in the world population and associated with functional disability and compromises the physical health of affected individuals. According to Traditional Chinese Medicine (TCM), depression is associated with disability, there is not enough energy for positive feelings or associated with stagnation, when there is energy, but the flow of energy and emotions is blocked. Deficiency is also associated with excess in manic depression or irregularity in depression associated with anxiety. Auricular acupuncture, also known as auriculotherapy, it is part of a set of techniques based on TCM. For this, the auricular pavilion is related to 12 meridians, stimulating points in the ear and restoring the balance between blood and Qi (energy or vital force).Methods: This is a systematic review protocol for clinical trials prepared in accordance with the guidelines of the protocol Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA-P). Studies in which participants have any depressive disorder, diagnosed through standardized criteria such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), the International Classification of Diseases (ICD) and other diagnostic criteria used internationally will be included. There will be no restrictions on age, gender, ethnicity, education or economic status. Studies will be accepted that have as experimental intervention any type of auricular acupuncture (using needles, seeds, magnetic stones, lasers, ultrasound, bleeding or electrical treatment). The control interventions that will be considered for the studies will be conventional medical treatment for each depressive disorder, no treatment, placebo and other active therapies. Discussion: Auricular acupuncture can be a potential alternative complementary treatment, it is low cost and has minimal side effects presented until now. With this review we hope to complete gaps in the knowledge of auricular acupuncture, promoting an updated and comprehensive synthesis of research on this topic. Record of systematic review: In accordance with the guidelines, our systematic review protocol was registered with the International Prospective Registry of systematic reviews (PROSPERO) on 10/27/2020 (registration number CRD42020211302).


Sign in / Sign up

Export Citation Format

Share Document